Frontiers in Oncology (Jan 2022)

Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group

  • Konrad Klinghammer,
  • Konrad Klinghammer,
  • Luigi Lorini,
  • Daan Nevens,
  • Christian Simon,
  • Jean-Pascal Machiels,
  • Paolo Bossi

DOI
https://doi.org/10.3389/fonc.2022.730785
Journal volume & issue
Vol. 12

Abstract

Read online

Multiple factors differentially influence treatment decisions in the first line treatment of recurrent/metastatic HNSCC. The EORTC Young investigator group launched a survey among treating physicians to explore the main influencing factors for treatment stratification. The questionnaire was posted as a web-survey link from May to August 2020. Next to defining the factors that mostly influence therapeutic decision the survey was complemented by a clinical case discussion of five patient cases. A total of 118 responses from 19 countries were collected. The key factors identified to guide treatment decision were performance status, PD-L1 Expression, time from last systemic treatment above or below 6 months, and disease burden.Prospective evaluation of patient characteristics and additional potential predictive biomarkers for novel treatment options remains an important question to stratify personalized treatment for RM HNSCC.

Keywords